{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T01:12:19Z","timestamp":1774746739044,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T00:00:00Z","timestamp":1513900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Obstet and Gynaecol"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>The aim of this study was to compare the efficacy and tolerability of solifenacin and mirabegron in patients with overactive bladder (OAB) syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We carried out a retrospective analysis in 342 women affected by OAB syndrome; 168 were treated with solifenacin 5\u2009mg\/daily and 174 with mirabegron 50\u2009mg\/daily. A clinical evaluation, 3\u2010day voiding diary, and urodynamic testing was performed. Patients completed the Overactive Bladder Questionnaire \u2013 Short Form, the King's Health Questionnaire, and the Patient Global Impression of Improvement questionnaire. The adverse effects were evaluated. The two groups were compared at baseline and at 12\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 12\u2009weeks, a significant reduction in the mean number\/24\u2009h of voids and urgent micturition episodes\/24\u2009h was observed in both groups. Detrusor overactivity decreased from 58.3% to 13.1% in the solifenacin group and from 58% to 11% in the mirabegron group. Twenty (12%) and 18 (10.7%) patients taking solifenacin reported constipation and dry mouth, respectively, versus four (2.3%) and five (2.9%) patients taking mirabegron, respectively, but there was no difference between the groups in the change in vital signs. The Overactive Bladder Questionnaire \u2013 Short Form and King's Health Questionnaire scores did not demonstrate significant differences and the abandonment rates in the solifenacin and mirabegron groups were 25.5% and 20%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Solifenacin and mirabegron showed the same efficacy in the treatment of OAB but solifenacin had more adverse effects.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jog.13541","type":"journal-article","created":{"date-parts":[[2017,12,23]],"date-time":"2017-12-23T17:52:10Z","timestamp":1514051530000},"page":"524-531","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis"],"prefix":"10.1111","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4149-170X","authenticated-orcid":false,"given":"Michele C.","family":"Schiavi","sequence":"first","affiliation":[{"name":"Department of Gynecological\u2013Obstetric Sciences and Urological Sciences University of Rome \u201cSapienza,\u201d Umberto I Hospital  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierangelo","family":"Faiano","sequence":"additional","affiliation":[{"name":"Department of Gynecological\u2013Obstetric Sciences and Urological Sciences University of Rome \u201cSapienza,\u201d Umberto I Hospital  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ottavia","family":"D'Oria","sequence":"additional","affiliation":[{"name":"Department of Gynecological\u2013Obstetric Sciences and Urological Sciences University of Rome \u201cSapienza,\u201d Umberto I Hospital  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzio A.","family":"Zullo","sequence":"additional","affiliation":[{"name":"Department of Surgery \u2013 Week\u2010Surgery Campus Biomedico University of Rome  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovico","family":"Muzii","sequence":"additional","affiliation":[{"name":"Department of Gynecological\u2013Obstetric Sciences and Urological Sciences University of Rome \u201cSapienza,\u201d Umberto I Hospital  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Benedetti Panici","sequence":"additional","affiliation":[{"name":"Department of Gynecological\u2013Obstetric Sciences and Urological Sciences University of Rome \u201cSapienza,\u201d Umberto I Hospital  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-009-0976-9"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09993.x"},{"key":"e_1_2_6_6_1","first-page":"935","article-title":"Mirabegron for overactive bladder: A novel, first\u2010in\u2010class \u03b23\u2010agonist therapy","volume":"10","author":"Imran M","year":"2013","journal-title":"Urol J"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389450116666150518102021"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.016"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.01.087"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-017-4307-y"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(11)70554-X"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1997.tb11006.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.379"},{"key":"e_1_2_6_14_1","unstructured":"National Institute for Health and Clinical Excellence. Lower urinary tract symptoms in men: Management \u2013 NICE Guideline CG97e 2010. [Accessed 20 August 2017]. Available from URL:https:\/\/www.nice.org.uk\/Guidance\/CG97"},{"key":"e_1_2_6_15_1","unstructured":"National Institute for Health and Clinical Excellence. Urinary incontinence in women: NICE Guideline CG171 2013. [Accessed 20 August 2017]. Available from URL:https:\/\/www.nice.org.uk\/guidance\/cg171\/chapter\/1-recommendations"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2016.11.006"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11023.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.047"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(03)45003-6"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn992"},{"key":"e_1_2_6_21_1","first-page":"256","article-title":"Age\u2010related alterations of the blood\u2013brain\u2010barrier (BBB) permeability to protein molecules of different size","volume":"26","author":"Kleine TO","year":"1993","journal-title":"Z Gerontol"},{"key":"e_1_2_6_22_1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.15537\/smj.2015.10.12016","article-title":"Comparison of solifenacin and fesoterodine in treatment of overactive bladder","volume":"36","author":"Ercan \u00d6","year":"2015","journal-title":"Saudi Med J"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1701-2163(16)35440-8"},{"key":"e_1_2_6_24_1","unstructured":"US Food and Drug Administration. Drug databases: Drugs@FDA. [Cited 11 September 2012]. Available from URL:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202611s000lbl.pdf"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287215589250"},{"key":"e_1_2_6_26_1","article-title":"Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: Improvement in overactive bladder symptoms","author":"Schiavi MC","year":"2017","journal-title":"Gynecol Endocrinol"}],"container-title":["Journal of Obstetrics and Gynaecology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjog.13541","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jog.13541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T15:23:04Z","timestamp":1695655384000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/jog.13541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,22]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/jog.13541"],"URL":"https:\/\/doi.org\/10.1111\/jog.13541","archive":["Portico"],"relation":{},"ISSN":["1341-8076","1447-0756"],"issn-type":[{"value":"1341-8076","type":"print"},{"value":"1447-0756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,22]]}}}